Patents by Inventor Anthony John Shuker

Anthony John Shuker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective &bgr;3 adrenergic agonists
    Patent number: 6617347
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: September 9, 2003
    Assignee: Eli Lilly and Company
    Inventors: Thomas Alan Crowell, Charles David Jones, Anthony John Shuker
  • Selective &bgr;3 adrenergic agonists
    Patent number: 6265581
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: July 24, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective &bgr;3 adrenergic agonists
    Patent number: 6232337
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating Type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of formula (I) or a pharmaceutically acceptable salt thereof. The variables of formula (I) have the meanings defined herein.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: May 15, 2001
    Assignee: Eli Lilly and Company
    Inventors: Thomas Alan Crowell, Charles David Jones, Anthony John Shuker
  • Selective .beta.-3 adrenergic agonists
    Patent number: 6093735
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta..sub.3 adrenergic agonists
    Patent number: 6075040
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: June 13, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 6060492
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: May 9, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 6046227
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta..sub.3 receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: April 4, 2000
    Assignee: Eli Lilly and Company
    Inventors: Thomas Alan Crowell, Charles David Jones, Anthony John Shuker
  • Selective .beta.3 adrenergic agonist
    Patent number: 5977154
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: November 2, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Christine Ann Droste, Cynthia Darshini Jesudason, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 5939443
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Donald Paul Matthews, John Hampton McDonald, III, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.-3 adrenergic agonists
    Patent number: 5840738
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: November 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 5786356
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: July 28, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Anthony John Shuker, Mark Alan Winter